Catalent flags problems at its manufacturing plants; CFO departs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Nephron Double Upgrades Catalent (CTLT) to Buy, 'The Best Activist Candidate'
April 14, 2023 10:37 AM EDTNephron analyst Jack Meehan upgraded Catalent (NYSE: CTLT) from Sell to Buy.
"The Best Activist Candidate in Life Sciences"For an analyst ratings summary and ratings history on Catalent click here. For more ratings news on Catalent click here.
Shares of Catalent closed at $63.31 yesterday.
... More